Relevant bibliographies by topics / Substance P / Journal articles

Journal articles on the topic 'Substance P'

To see the other types of publications on this topic, follow the link: Substance P.
Author: Grafiati
Published: 4 June 2021
Last updated: 30 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Substance P.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Bernstein, Joel E. "Substance P and substance P antagonists." Current Opinion in Anaesthesiology 7, no. 5 (October 1994): 462–64. http://dx.doi.org/10.1097/00001503-199410000-00016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Snijdelaar, Dirk G., Ris Dirksen, Rob Slappendel, and Ben J. P. Crul. "Substance P." European Journal of Pain 4, no. 2 (June 2000): 121–35. http://dx.doi.org/10.1053/eujp.2000.0171.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Feighner, J. P. "Substance P." European Neuropsychopharmacology 8 (November 1998): S85. http://dx.doi.org/10.1016/s0924-977x(98)80054-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Harrison, S. "Substance P." International Journal of Biochemistry & Cell Biology 33, no. 6 (June 2001): 555–76. http://dx.doi.org/10.1016/s1357-2725(01)00031-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Iversen, Leslie. "Substance P equals pain substance?" Nature 392, no. 6674 (March 1998): 334–35. http://dx.doi.org/10.1038/32776.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

&NA;. "Mecasermin/substance P." Reactions Weekly &NA;, no. 1050 (May 2005): 14. http://dx.doi.org/10.2165/00128415-200510500-00044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lowe, J. A. III. "Substance P antagonists." Drugs of the Future 17, no. 12 (1992): 1115. http://dx.doi.org/10.1358/dof.1992.017.12.194882.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nanakida, Kunya, Dang Trang Nguyen, and Kozo Taguchi. "Synthesization and Photocatalytic Activity Evaluation of Float-Type g-C3N4 Microtubes." Defect and Diffusion Forum 428 (August 22, 2023): 119–23. http://dx.doi.org/10.4028/p-xnuv8q.

Full text
Abstract:
Float-type g-C3N4 microtubes were created by hydrothermal method and calcination using g-C3N4. Substances after hydrothermal synthesis and float-type g-C3N4 microtubes were investigated by XRD and SEM. The photocatalytic activity of float-type g-C3N4 microtubes was evaluated by methylene blue decomposition. According to these results, the substance, such as a needle, was found to have the same crystal structure as g-C3N4. In addition, it was confirmed that the needle-like substance was hollow inside, according to the SEM result. This substance can float on water. Therefore, Float type g-C3N4 microtubes can receive more light, and the decomposition rate has increased compared to g-C3N4.
APA, Harvard, Vancouver, ISO, and other styles
9

Jensen, Kai, Christian Tuxen, Ulrik Pedersen-Bjergaard, and Inger Jansen. "Pain, Tenderness, Wheal and Flare Induced by Substance-P, Bradykinin and 5-Hydroxytryptamine in Humans." Cephalalgia 11, no. 4 (September 1991): 175–82. http://dx.doi.org/10.1046/j.1468-2982.1991.1104175.x.

Full text
Abstract:
The algesic effect of substance-P with and without the addition of bradykinin or 5-hydroxytryptamine was studied in 13 healthy volunteers. Test substances dissolved in saline were injected into the temporal muscle and the forearm skin and the effects compared with those of saline. In the temporal muscle, none of the test substances induced more pain than saline, but substance-P with bradykinin lowered the pressure pain threshold by 18% ( p < 0.02). All test substances induced pain, wheal and flare in the forearm skin. Substance-P induced a more pronounced flare reaction than bradykinin, whereas the latter induced more pain than substance-P. This dissociation between pain and flare may indicate that C-fibres in the human skin represent more than one type of nociceptor.
APA, Harvard, Vancouver, ISO, and other styles
10

Kowall, N. W., B. J. Quigley, F. Lu, B. E. Kosofsky, and R. J. Ferrante. "Substance P and substance P receptor histochemistry in human neurodegenerative diseases." Regulatory Peptides 37 (September 1992): S27. http://dx.doi.org/10.1016/0167-0115(92)90883-v.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Kowall, N. W., B. J. Quigley, J. E. Krause, F. Lu, B. E. Kosofsky, and R. J. Ferrante. "Substance P and substance P receptor histochemistry in human neurodegenerative diseases." Regulatory Peptides 46, no. 1-2 (July 1993): 174–85. http://dx.doi.org/10.1016/0167-0115(93)90028-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Goto, T., Mizuho A. Kido, Takayoshi Yamaza, and Teruo Tanaka. "Substance P and substance P receptors in bone and gingival tissues." Medical Electron Microscopy 34, no. 2 (June 1, 2001): 77–85. http://dx.doi.org/10.1007/s007950170001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Weinstock, J. V., A. Blum, J. Walder, and R. Walder. "Eosinophils from granulomas in murine schistosomiasis mansoni produce substance P." Journal of Immunology 141, no. 3 (August 1, 1988): 961–66. http://dx.doi.org/10.4049/jimmunol.141.3.961.

Full text
Abstract:
Abstract Granulomas are chronic, usually focal, tissue-destructive inflammatory reactions that usually form around slowly degradable, poorly soluble substances. They are dynamic lesions, regulated by complex immune mechanisms. Tachykinins are a family of neuropeptides characterized by the common C-terminal amino acid sequence -Phe-X-Gly-Leu-Met-NH2. One such tachykinin, substance P, has been reported to modulate immunologic responses. In this investigation, granulomas were examined for substance P. Granulomas were isolated from the livers of mice infected with murine schistosomiasis, and substance P was extracted. Immunoreactive substance P was detected by RIA. The authenticity of the molecule was confirmed by elution profile on HPLC. Immunoreactive substance P, identified by immunostaining, localized to eosinophils derived from collagenase-dispersed granulomas. Granulomas were then probed for expression of the gene for substance P (preprotachykinin). Preprotachykinin mRNA was localized to granuloma eosinophils by in situ oligonucleotide hybridization. It is concluded that substance P is present within the granuloma as a result of preprotachykinin production by eosinophils.
APA, Harvard, Vancouver, ISO, and other styles
14

KIM, Eun Jung, Chan-Hee KIM, Hye-Jin GO, In Hae KIM, Sang Hyun AN, Hee-Young SOHN, Hee Yeon PARK, et al. "Structure and Arterial Relaxing Activity of Substance P-related Peptides and Substance P analogs." Korean Journal of Fisheries and Aquatic Sciences 38, no. 3 (June 1, 2005): 143–47. http://dx.doi.org/10.5657/kfas.2005.38.3.143.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Polak, Julia M. "More about substance P." Equine Veterinary Journal 17, no. 1 (January 1985): 1. http://dx.doi.org/10.1111/j.2042-3306.1985.tb02022.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Hokfelt, Tomas, and Eugenia Kuteeva. "Substance P: A Neuropeptide." American Journal of Psychiatry 163, no. 4 (April 2006): 578. http://dx.doi.org/10.1176/ajp.2006.163.4.578.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

SEELIG, ANNA, and REINHARD DOELZ. "Substance P and Antagonists." Annals of the New York Academy of Sciences 632, no. 1 Substance P a (September 1991): 468–70. http://dx.doi.org/10.1111/j.1749-6632.1991.tb33159.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Diz, Debra I., Burt Falgui, Susan M. Bosch, Brian M. Westwood, Jessica Kent, Detlev Ganten, and Carlos M. Ferrario. "Hypothalamic Substance P Release." Hypertension 29, no. 1 (January 1997): 510–13. http://dx.doi.org/10.1161/01.hyp.29.1.510.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Pernow, Bengt. "PHARMACOLOGY OF SUBSTANCE P." Annals of the New York Academy of Sciences 104, no. 1 (December 15, 2006): 393–402. http://dx.doi.org/10.1111/j.1749-6632.1963.tb17684.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Powell, Frank C., Niamh Corbally, and David Powell. "Substance P and rosacea." Journal of the American Academy of Dermatology 28, no. 1 (January 1993): 132–33. http://dx.doi.org/10.1016/s0190-9622(08)80863-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Bernstein, Joel E. "Capsaicin and substance P." Clinics in Dermatology 9, no. 4 (October 1991): 497–503. http://dx.doi.org/10.1016/0738-081x(91)90078-y.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

&NA;. "Manipulation and Substance P." Back Letter 6, no. 1 (November 1991): 1. http://dx.doi.org/10.1097/00130561-199111000-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Russell, I. Jon. "Substance P and Fibromyalgia." Journal of Musculoskeletal Pain 6, no. 3 (January 1998): 29–35. http://dx.doi.org/10.1300/j094v06n03_06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Bobyock, E., E. J. Barbieri, and W. S. Chernick. "Effects of Substance P and Substance P Antagonists on Rat Salivary Secretion." Journal of Dental Research 65, no. 12 (December 1986): 1427–31. http://dx.doi.org/10.1177/00220345860650121001.

Full text
Abstract:
The intra-arterial infusion of substance P produced dose-related responses of both parotid and submandibular salivary secretion in anesthetized rats. The substance P-induced secretion in both glands was inhibited by the substance P analogues [D-Arg 1, D-Trp7,9, Leu11 ]-substance P and [D-Arg1, D-Pro2, D-Trp7,9, Leu11 ]-substance P, but not by [D-Pro2 , D-Trp7,9]-substance P. The profiles of protein and calcium levels obtained with substance P-induced salivary secretion for both glands were similar to those produced by acetylcholine stimulation and were not altered by the substance P analogues.
APA, Harvard, Vancouver, ISO, and other styles
25

Kopp, Ulla C., Michael Z. Cicha, Donna M. Farley, Lori A. Smith, and Bradley S. Dixon. "Renal Substance P–Containing Neurons and Substance P Receptors Impaired in Hypertension." Hypertension 31, no. 3 (March 1998): 815–22. http://dx.doi.org/10.1161/01.hyp.31.3.815.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Gontijo, José R., Lori A. Smith, and Ulla C. Kopp. "CGRP Activates Renal Pelvic Substance P Receptors by Retarding Substance P Metabolism." Hypertension 33, no. 1 (January 1999): 493–98. http://dx.doi.org/10.1161/01.hyp.33.1.493.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Khan, S., J. Sandhu, R. Whelpton, and A. T. Michael-Titus. "Substance P fragments and striatal endogenous dopamine outflow: interaction with substance P." Neuropeptides 32, no. 6 (December 1998): 519–26. http://dx.doi.org/10.1016/s0143-4179(98)90080-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Sakurada, T., H. Kuwahara, K. Takahashi, S. Sakurada, K. Kisara, and L. Terenius. "Substance P(1–7) antagonizes substance P-induced aversive behaviour in mice." Neuroscience Letters 95, no. 1-3 (December 1988): 281–85. http://dx.doi.org/10.1016/0304-3940(88)90671-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Boyd, N. D., R. Cerpa, E. T. Kaiser, S. E. Leeman, and C. F. White. "Photoaffinity labeling the substance P receptor using a derivative of substance P containing p-benzoylphenylalanine." Biochemistry 30, no. 2 (January 15, 1991): 336–42. http://dx.doi.org/10.1021/bi00216a005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Nikolaus, S., J. P. Huston, and R. K. W. Schwarting. "Pretreatment With Fragments of Substance-P or With Cholecystokinin Differentially Affects Recovery From Sub-Total Nigrostriatal 6-Hydroxydopamine Lesion." Neural Plasticity 6, no. 4 (1999): 77–89. http://dx.doi.org/10.1155/np.1999.77.

Full text
Abstract:
The neuropeptide substance P is known to have mnemogenic and reinforcing actions and can exert neurotrophic and regenerative effectsin vitroas well asin vivo. Furthermore, our previous work in the rat showed that either pre- or post-lesion treatment with substance P can promote functional recovery in cases of partial nigrostriatal dopamine lesions. Other work has provided evidence that the effects of substance P might be differentially encoded by its C- and N-terminal fragments. The C-terminal fragment was found to be reinforcing, whereas the mnemogenic as well as neurotrophic properties have been ascribed to the N-terminal sequences. Given these relations, we asked here whether pre-lesion treatment with either a C- or an N-terminal fragment of substance P might differentially affect the behavioral and neurochemical outcome of nigrostriatal dopamine lesions. Therefore, either substanceP1−7or substanceP5−11(37 nmol/kg each) was administered intraperitoneally daily for eight consecutive days before unilateral 6-hydroxy-dopamine lesions of the substantia nigra. Control rats received prelesion treatment with vehicle. Furthermore, we investigated the effects of pre-treatment with Boc-cholecystokinin-4 (0.91 nmol/kg), as we had found an increase in dopamine metabolism in animals that were pre-treated with cholecystokinin-8 in a former study. In accordance with our previous work, drug treatment effects were observed when excluding animals with most severe dopamine lesions: In animals with partial lesions (residual neostriatal dopamine levels of more than 10%), lesion-dependent asymmetries in turning behavior were observed in animals that were pre-treated with vehicle-, substanceP1−7, or Boc-cholecysto-kinin–4,. whereas turning after pre-treatment with substanceP5−11was not significantly asymmetrical. Furthermore, the ipsi- and contra-lateral neostriatal dopamine levels did not differ significantly in this group. Moreover, pre treatment with substanceP5−11affected dopamine metabolism in the neostriatum and in the venral striatum, as indicated by increased ratios of dihydroxyphenyllic acid to dopamine. The data provide the first evidence that the promotive effects of substance-P treatment in the unilateral dopamine lesion model might be mediated by its C-terminal and might depend on actions on residual dopamine mechanisms.
APA, Harvard, Vancouver, ISO, and other styles
31

Shore, S. A., and J. M. Drazen. "Airway responses to substance P and substance P fragments in the guinea pig." Pulmonary Pharmacology 1, no. 3 (January 1988): 113–18. http://dx.doi.org/10.1016/s0952-0600(88)80008-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Roth, Kevin A., George Makk, Olof Beck, Kym Faull, Kazuhiko Tatemoto, Christopher J. Evans, and Jack D. Barchas. "Isolation and characterization of substance P, substance P 5–11, and substance K from two metastatic ileal carcinoids." Regulatory Peptides 12, no. 3 (November 1985): 185–99. http://dx.doi.org/10.1016/0167-0115(85)90060-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Mudenda, Steward. "Prevalence of Substance Use Disorders During the Covid-19 Pandemic: A Cross-Sectional Study in Kanyama Township of Lusaka District, Zambia." TEXILA INTERNATIONAL JOURNAL OF PUBLIC HEALTH 11, no. 3 (September 29, 2023): 117–31. http://dx.doi.org/10.21522/tijph.2013.11.03.art010.

Full text
Abstract:
The coronavirus disease (Covid-19) pandemic has caused suffering and pain to mankind leading to many individuals practising self-medication and substance abuse that could elevate substance use disorders (SUDs). This study assessed the impact of Covid-19 on SUDs among Kanyama residents of Lusaka district, Zambia. We conducted a retrospective cross-sectional study using patient files at Kanyama First-Level Hospital from September 2021 to October 2021. Data analysis was done using IBM SPSS version 26.0. Of the 101 participants, 86.1% were male. The study showed that Covid-19 had an impact on SUDs with alcohol (83.2%) being the most abused substance. There was no significant difference in the type of substances abused (p=0.870) and intoxication symptoms (p=0.331) between the pre-Covid and post-Covid groups. There was a significant difference between substance use (p=0.001) and withdrawal symptoms (p=0.002) in both cohorts, with the post-Covid group consuming more substances and experiencing more withdrawal symptoms. Factors that influenced substance abuse included recent unemployment (p<0.001), boredom (p<0.001), overcrowding at home (p<0.001), and gender-based violence (p<0.001) influenced the change in the pattern of substance use. Recreational use was not associated with a change in the pattern of substance abuse (p=0. 667). This study found that the Covid-19 pandemic increased the practices of substance abuse among Kanyama residents, especially those who were unemployed, bored, overcrowded at home and experienced gender-based violence. There is a need to heighten the monitoring and restriction of substance use, especially among adolescents and youths to curb some mental health problems. Keywords: Covid-19; Pandemic; Self-medication; Substance abuse; substance use disorders; Zambia.
APA, Harvard, Vancouver, ISO, and other styles
34

Mirian Aguocha, Chinyere, and Emeka Nwefoh. "Prevalence and correlates of substance use among undergraduates in a developing country." African Health Sciences 21, no. 2 (August 2, 2021): 875–83. http://dx.doi.org/10.4314/ahs.v21i2.49.

Full text
Abstract:
Background: Psychoactive substance use is a major global public health issue. Use of psychoactive substances has been associated with negative consequences among students. Objective: The study assessed the prevalence and socio-demographic correlates of psychoactive substance use among un- dergraduate students in a Nigerian university. Materials and Methods: This was a cross-sectional descriptive study of 763 undergraduate students of Imo State Uni- versity, Owerri, Nigeria, recruited using multi-stage sampling technique. Data on the socio-demographic characteristics and pattern of psychoactive substance use were collected using a structured questionnaire. Results: The lifetime rate of psychoactive substance use was 84.5%. Alcohol had the highest rate of lifetime (82.5%) and 12-month (61.1%) use. There was a similar rate of lifetime use of psychoactive substances among males (86.1%) and females (83.4%). Age (p<0.05) and place of residence (p<0.05) were significantly associated with lifetime psychoactive substance use. Catholics (OR:1.43; 1.03 – 1.99), whose friend (OR:1.94; 1.39 – 2.71), roommate (OR:3.06; (1.62 – 5.78) or broth- er (OR:1.22; 0.77 – 1.93) uses psychoactive substances were significantly more likely to have used substances in the past 12-months. Conclusion: There is a high rate of psychoactive substance use among the students. Age, religion, place of residence, family and peer use of substances are important determinants of psychoactive substance use. Keywords: Substance use; undergraduates; Nigeria.
APA, Harvard, Vancouver, ISO, and other styles
35

Redkiewicz, Patrycja. "The Regenerative Potential of Substance P." International Journal of Molecular Sciences 23, no. 2 (January 11, 2022): 750. http://dx.doi.org/10.3390/ijms23020750.

Full text
Abstract:
Wound healing is a highly coordinated process which leads to the repair and regeneration of damaged tissue. Still, numerous diseases such as diabetes, venous insufficiencies or autoimmune diseases could disturb proper wound healing and lead to chronic and non-healing wounds, which are still a great challenge for medicine. For many years, research has been carried out on finding new therapeutics which improve the healing of chronic wounds. One of the most extensively studied active substances that has been widely tested in the treatment of different types of wounds was Substance P (SP). SP is one of the main neuropeptides released by nervous fibers in responses to injury. This review provides a thorough overview of the application of SP in different types of wound models and assesses its efficacy in wound healing.
APA, Harvard, Vancouver, ISO, and other styles
36

Seidel, Matthias, Julia Tsalik, Hans Vetter, and Wolfgang Muller. "Substance P in Rheumatic Diseases." Current Rheumatology Reviews 3, no. 1 (February 1, 2007): 17–30. http://dx.doi.org/10.2174/157339707779815830.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Robinson, Prema, Emma Rodriguez, and Miguel Muñoz. "Substance P—Friend or Foe." Journal of Clinical Medicine 11, no. 13 (June 22, 2022): 3609. http://dx.doi.org/10.3390/jcm11133609.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Yamada, Masakazu, Masaro Ogata, Masataka Kawai, Yukihiko Mashima, and Teruo Nishida. "Substance P in Human Tears." Cornea 22, Supplement 1 (October 2003): S48—S54. http://dx.doi.org/10.1097/00003226-200310001-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Kim, Min Sup, Sang Jun Park, Bon Kang Gu, Chang-Mo Kang, and Chun-Ho Kim. "Substance-P Immobilized Chitosan Nanofibers." Molecular Crystals and Liquid Crystals 603, no. 1 (November 2, 2014): 146–56. http://dx.doi.org/10.1080/15421406.2014.968078.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Lowe, John A., Susan E. Drozda, Stafford McLean, D. K. Bryce, Rosemary T. Crawford, R. Michael Snider, Kelly P. Longo, Atsushi Nagahisa, and Megumi Tsuchiya. "Aza-Tricyclic Substance P Antagonists." Journal of Medicinal Chemistry 37, no. 18 (September 1994): 2831–40. http://dx.doi.org/10.1021/jm00044a002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Raap, Mieke, Urda Rüdrich, Sonja Ständer, Manuela Gehring, Alexander Kapp, and Ulrike Raap. "Substance P activates human eosinophils." Experimental Dermatology 24, no. 7 (May 8, 2015): 557–59. http://dx.doi.org/10.1111/exd.12717.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Leeman, S. E., and S. L. Ferguson. "Substance P: an historical perspective." Neuropeptides 34, no. 5 (October 2000): 249–54. http://dx.doi.org/10.1054/npep.2000.0826.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

KIMBALL, EDWARD S. "Substance P, Cytokines, and Arthritis." Annals of the New York Academy of Sciences 594, no. 1 Neuropeptides (June 1990): 293–308. http://dx.doi.org/10.1111/j.1749-6632.1990.tb40489.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Katsanos, G. S., A. Anogeianaki, C. Orso, S. Tetè, V. Salini, P. L. Antinolfi, and G. Sabatino. "Substance P: An Inflammatory Peptide." European Journal of Inflammation 6, no. 2 (May 2008): 59–64. http://dx.doi.org/10.1177/1721727x0800600202.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Lembeck, Fred. "The archeology of substance P." Neuropeptides 42, no. 4 (August 2008): 444–53. http://dx.doi.org/10.1016/j.npep.2008.04.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Peng, Lei, George O. Agogo, Jianqiang Guo, and Ming Yan. "Substance P and fibrotic diseases." Neuropeptides 76 (August 2019): 101941. http://dx.doi.org/10.1016/j.npep.2019.101941.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Kosson, Piotr, Piotr Wojciechowski, Aleksandra Misicka, Danuta Tymecka, Engin Bojnik, Maria Szereda-Przestaszewska, Schandor Benyhe, Daniel B. Carr, and Andrzej W. Lipkowski. "Opioid-substance P chimeric peptides." Pharmacological Reports 62 (September 2010): 29. http://dx.doi.org/10.1016/s1734-1140(10)71120-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Weber, K. T. "White mineral and substance P." Cardiovascular Research 31, no. 5 (May 1, 1996): 675–76. http://dx.doi.org/10.1016/s0008-6363(96)00032-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Otsuka, Masanori. "Substance P: history and perspectives." Japanese Journal of Pharmacology 67 (1995): 79. http://dx.doi.org/10.1016/s0021-5198(19)46286-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Kürkçüoğlu, Nazif, and Ferda Alaybeyi. "Substance P immunoreactivity in rosacea." Journal of the American Academy of Dermatology 25, no. 4 (October 1991): 725–26. http://dx.doi.org/10.1016/s0190-9622(08)80678-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Substance P' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography